[1] Thalherimer U,Bellis L,Puoti C,et al. Should we routinely measure portal pressure in patients with cirrhosis,using hepatic venous pressure gradient （HVPG） as a guide for prophylaxis and therapy of bleeding and rebleeding. Eur J Intern Med,2011,22:5-7.
[2] Bellis L,Castellacci R,Montagnese F,et al. Hepatic venous pressure gradient determination in patients with hepatitis C virus-related and alcoholic cirrhosis. Eur J Gastroenterol Hepatol,2003,15:1085-1089.
[3] Wadhawan M,Dubey S.Hepatic venous pressure gradient in cirrhosis:Correlation with the size of varices bleeding,ascites,and Child’s status. Dig Dis Sci,2006,51:2264-2269.
[4] Nagula S,Jain D,Groszmann RJ,et al. Histological-hemodynamic correlation in cirrhosis-a histological classification of the severity of cirrhosis,J Hepatol,2006,44（1）:111-117.
[5] Ripoll C,Groszmann R,Garcia-Tsao G,et al. Portal hypertension collaborative group. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology,2007,133（2）:481-488.
[6] Groszmann R,Vorobioff JD. Measurement of portal pressure: When,how,and why to do it. Clin Liver Dis,2006,34（10）:499-512.
[7] De Franchis R. Updating consensus in portal hypertension. Report of the Baveno III consensus workshop on definitions,methodology and therapeutic strategies in portal hypertension. J Hepatol,2000,33:846-852.
[8] Triantos CK,Nikolopoulou V,Burroughs AK. Review article: the therapeutic and prognostic benefit of poral pressure reduction in cirrhosis. Aliment Pharmacol Ther,2008,28（8）:943-952.
[9] Burroughs AK,Thalheimer U. Hepatic venous pressure gradient in 2010:optimal measurement is key. Hepatology,2010,51（60）:1894-1896.
[10] Suk Kt,Kim Hc,Namkung S,et al. Diagnostic accuracy of hepatic venous pressure gradient measurement in the prediction of stage 1 compensated liver cirrhosis in patients with chronic hepatitis B. Eur J Gastroenterol Hepatol,2013,25（10）:1170-1176.
[11] Addley J,Tham Tc,Cash WJ. Use of portal pressure studies in the management of variceal haemorrhage. World J Gastrointest Endosc,2012,4（7）:281-289.
[12] de Franchis R, Baveno V Faculty. Revising consensus in portal hypertension:report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol,2010,53:762-768.
[13] Lisman T,Bongers TN,Adelmeijer J,et al. Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology,2006,44:53-61.
[14] La Mura V,Reverter JC,Flores-Arroyo A,et al. Von Willebrang factor levels predict clinical outcome in patients with cirrhosis and portal hypertension. Gut,2011,60:1133-1138.
[15] Abdelmoaty MA,Bogdady AM,Attia MM,et al. Circulating vascular endothelial growth factor and nitric oxide in patients with liver cirrhosis:A possible association with liver function impairment. India J Clina Biochem,2009,24:398-403. |
